Dupixent from Sanofi S.A. - asthma control that changes daily life

Reviewed: ad hoc news Bestseller & Flagship desk. Edited and checked on 2026-06-22, 20:07. Details in the imprint.

Dupixent sits in a patient’s fridge, next to the milk, a slim pen that promises fewer night-time asthma attacks and less wheezing on the stairs. The biologic from Sanofi S.A. has become a quiet anchor therapy for many people with severe type 2 asthma.

Where Dupixent stands today

Dupixent is a monoclonal antibody, given as a subcutaneous injection every 2 or 4 weeks, that blocks the IL-4 and IL-13 pathways driving type 2 inflammation in several diseases. In asthma, many patients use a prefilled pen at home after initial training by a nurse. The plastic housing feels sturdy in the hand, the injection click is short and clean, and the sting is usually over in seconds.

Originally approved for atopic dermatitis, Dupixent now carries indications for asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and prurigo nodularis in major markets. That breadth has turned it into one of Sanofi’s key growth engines, with the company reporting multi-billion-euro annual sales.

How it changes asthma therapy

For severe asthma, Dupixent is used on top of high-dose inhaled corticosteroids and long-acting bronchodilators when patients still suffer frequent exacerbations. In pivotal trials, the drug cut severe attacks by up to around 59 percent versus placebo in certain patient subgroups and allowed significant reductions in maintenance oral corticosteroids.

Professor Klaus Rabe, a well-known pulmonologist involved in biologic asthma research, has described IL-4/IL-13 blockade as a consistent way to target type 2 inflammation in appropriate patients, while still requiring careful phenotyping and follow-up. In practice, that means blood eosinophil counts, IgE levels and clinical history guide who really benefits.

Practical use and patient experience

In the clinic, nurses often demonstrate the first injection on a training pad before patients try it in the upper thigh or abdomen under supervision. Many patients report that the cold solution stings less if the pen warms for a few minutes in the hand after leaving the fridge. The audible click and small window that turns opaque give a clear sense the dose is delivered.

Adverse effects include injection-site reactions, conjunctivitis and eosinophilia, which doctors monitor with scheduled blood tests and eye checks. For many, however, the trade-off feels acceptable when nocturnal symptoms ease and steroid bursts become less frequent.

Regulatory reach and access

Dupixent is approved for asthma and other indications in the European Union, the United States and Japan, among other regions. In Germany, it is available on prescription through hospital outpatient clinics and office-based specialists, typically after a therapy assessment by a pneumologist or dermatologist.

Pricing and reimbursement depend on national health systems and negotiated discounts. Sanofi and partner Regeneron have repeatedly underlined Dupixent’s role as a long-term franchise and continue to seek label expansions and pediatric indications.

What investors should watch

Chief executive Paul Hudson regularly points to Dupixent as a pillar of Sanofi’s strategy to focus on immunology and specialty care rather than primary-care mass markets. Future data in chronic obstructive pulmonary disease and other inflammatory conditions could further broaden its reach, but will also face competition from other biologics.

Sanofi shares (ISIN FR0000120578) trade on Euronext Paris, where Dupixent’s performance and pipeline updates are closely watched by analysts when assessing the medium-term Sanofi share price.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.